Behnam and Klein (1) carried out in vitro assays on two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) inhibitors, including atazanavir reported by us (2), using an Mpro protein with C-terminal His-tag under various assay conditions, and find that both the Michaelis−Menten constant (Km) and inhibitory activity (IC50) are sensitive to the assay conditions. It is interesting to examine whether the assay conditions significantly affect the activities of an enzyme and its inhibitors. On the other hand, Behnam and Klein (1) do not account for possible effects of the C-terminal His-tag on the Km and IC50, despite the fact that the tag-free Mpro (without any N- or C-terminal tag) was used in our reported assays (2), whereas the C-terminal His-tagged Mpro was used in their assays (1).
As discussed recently (3), both the N and C termini of Mpro are close to the active-site cavity, according to available X-ray crystal structures. Thus, a His-tag on the N or C terminus could interfere in Mpro binding with a ligand (substrate or inhibitor). Depicted in Fig. 1 is a modeled structure of the C-terminal His-tagged Mpro protein. The modeling started from an available X-ray crystal structure (Protein Data Bank ID code 6M2N) (4). Notably, the His-tag was outside of the Mpro active site in the initial structure (Fig. 1A) built by using the Prime module (5, 6) of the Schrodinger 2013 software. After 50-ns molecular dynamics (MD) simulations, the His-tag moved to the Mpro active site (Fig. 1B), suggesting that the His-tag added to the C terminus may compete with the substrate/inhibitor for binding. For this reason, the C-terminal His-tag could lower the binding affinity of a given ligand (substrate or inhibitor) with Mpro. In fact, it has been reported that Km = 1.41 μM for the tag-free Mpro (3) and Km = 28.2 μM for the C-terminal His-tagged Mpro (7), suggesting that the C-terminal His-tag may lower the binding affinity with the substrate by ∼20-fold. The remarkable difference explains why the IC50 values determined by Behnam and Klein (1) and Ma and Wang (8) using C-terminal His-tagged Mpro are significantly larger than the corresponding IC50 values determined by us using the tag-free Mpro (2). It is also possible that the interaction between the His-tag and the active site is affected by the assay conditions. Hence, the results described by Behnam and Klein (1) are not surprising based on the structural information about the His-tagged Mpro protein discussed above.
Fig. 1.
Structure of the Mpro protein with His-tag (LEHHHHHH) added to the C terminus. (A) Initial structure of the C-terminal His-tagged Mpro protein with a ligand bound in the active site. (B) The last snapshot of the MD-simulated C-terminal His-tagged Mpro protein structure (in which the ligand in the active site was removed before the MD simulation) in a TIP3P water box. The system, after energy minimization, was first heated to 300 K in a 50-ps MD simulation (with NVT) followed by 50-ps MD simulation [with NPT, i.e., the constant amount of substance (N), pressure (P), and temperature (T)] for equilibration. Finally, a 50-ns MD simulation (with NPT) was performed without any restraints for the system.
Acknowledgments
We cordially acknowledge the National Key R&D Program of China (Grant 2017YFB0202600), National Natural Science Foundation of China (Grants 81903542, 81522041, and 21877134), Science Foundation of Guangdong Province (Grant 2020A111128007), NSF (Grant CHE-1111761), Taishan Scholars Program (Grant tsqn201909170), and Innovative Leader of Qingdao Program (Grant 19-3-2-26-zhc).
Footnotes
The authors declare no competing interest.
Change History
September 8, 2021: The licensing has been updated.
References
- 1.Behnam M., Klein C., Inhibitor potency and assay conditions: A case study on SARS-CoV-2 main protease. Proc. Natl. Acad. Sci. U.S.A., 10.1073/pnas.2106095118 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Li Z., et al., Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc. Natl. Acad. Sci. U.S.A. 117, 27381–27387 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Li Z., et al., Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. U.S.A. 118, e2024937118 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Su H. X., et al., Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol. Sin. 41, 1167–1177 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Jacobson M. P., et al., A hierarchical approach to all-atom protein loop prediction. Proteins 55, 351–367 (2004). [DOI] [PubMed] [Google Scholar]
- 6.Jacobson M. P., Friesner R. A., Xiang Z., Honig B., On the role of the crystal environment in determining protein side-chain conformations. J. Mol. Biol. 320, 597–608 (2002). [DOI] [PubMed] [Google Scholar]
- 7.Ma C., et al., Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30, 678–692 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ma C., Wang J., Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. U.S.A. 118, e2024420118 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]

